Cabozantinib hydrochloride is an orally administered, small-molecule tyrosine kinase inhibitor (TKI) used as an antineoplastic (anti-cancer) agent. It is marketed under the brand names Cometriq (capsules) and Cabometyx (tablets), which are not interchangeable due to differences in formulation. It is grouped under the following drug class(es): Antineoplastic agents and VEGF inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a unknown/inactive API with a synthetic source/manufacturing origin. Other names for this substance include Cabozantinib HCl and HY-13016A. Its PubChem CID is 122573030.
Cabozantinib hydrochloride
| CAS No | 1817759-42-4 |
|---|---|
| Molecular Formula | C28H25ClFN3O5 |
| Molecular Weight | 538.0 g/mol |
| Synonyms | 1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N‘-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;hydrochloride |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Cabozantinib hydrochloride is an orally administered, small-molecule tyrosine kinase inhibitor (TKI) used as an antineoplastic (anti-cancer) agent. It is marketed under the brand names Cometriq (capsules) and Cabometyx (tablets), which are not interchangeable due to differences in formulation.
The listed CAS number is 1817759-42-4.
The listed molecular formula is C28H25ClFN3O5.
The listed molecular weight is 538.0 g/mol.
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N‘-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;hydrochloride.
The source lists Cabozantinib HCl and HY-13016A.